BioVaxys Technology Corp, a Vancouver-based company that specializes in immunotherapies, announced on Tuesday that it had been granted a patent (#12,042,537) by the US Patent and Trademark Office for inducing an antibody immune response using its DPX™ delivery platform. That patent was recently issued in Japan and is currently pending in the European Union.
According to the company, DPX is a cutting-edge lipid-based delivery system designed for encapsulating a diverse array of bioactive molecules, leading to enhanced and sustained immune responses.
Today, the company announced it had signed a binding letter of intent with AP Visionaries of Ontario to jointly develop a proprietary DPX formulation to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs.
The companies are conducting the study in collaboration with The Schroeder Allergy and Immunology Research Institute (SAIRI) at McMaster University in Ontario.
Said Kenneth Kovan, President & COO of BioVaxys:
Our ability to tackle this unmet medical need is directly attributable to the immune educating capability and highly flexible antigen loading capacity of our DPX platform. With the DPX platform already the backbone of multiple BioVaxys clinical programs in oncology and infectious disease, we see a staggering opportunity for continued expansion into other novel DPX-formulations with polynucleotides, peptides, proteins, virus-like articles, and small molecules.
Said James Passin, CEO of BioVaxys:
We look forward to completing preclinical studies with our development partners, and anticipate an emerging profile for a single dose, long duration, product consistent with other DPX formulations.
